Skip to main content

Abbott Laboratories (ABT)

NYSE: ABT · IEX Real-Time Price · USD
125.05 1.74 (1.41%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap222.07B
Revenue (ttm)40.23B
Net Income (ttm)6.38B
Shares Out1.78B
EPS (ttm)4.03
PE Ratio31.02
Forward PE24.94
Dividend$1.80 (1.44%)
Ex-Dividend DateOct 14, 2021
Volume4,984,034
Open124.54
Previous Close123.31
Day's Range123.09 - 125.60
52-Week Range101.56 - 129.20
Beta0.67
AnalystsBuy
Price Target134.28 (+7.4%)
Est. Earnings Daten/a

About ABT

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidi...

IndustryHealth Care Equipment & Supplies
Founded1888
CEORobert Ford
Employees109,000
Stock ExchangeNYSE
Ticker SymbolABT
Full Company Profile

Financial Performance

In 2020, ABT's revenue was $34.61 billion, an increase of 8.48% compared to the previous year's $31.90 billion. Earnings were $4.50 billion, an increase of 21.91%.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 134.28, which is an increase of 7.38% from the latest price.

Price Target
$134.28
(7.38% upside)
Analyst Consensus: Buy

News

3 Things Investors Should Love About Abbott's Q3 Results

There was nothing but good news for Abbott in Q3.

12 hours ago - The Motley Fool

Why Abbott Laboratories Shot Higher Today

All four of the company's divisions posted strong growth, but one in particular was a standout.

1 day ago - The Motley Fool

Is it too late to buy Abbott shares after raising FY2021 earnings guidance?

On Wednesday, Abbott Laboratories (NYSE:ABT) shares surged nearly 4% after announcing solid fiscal third-quarter results. The company reported its most recent quarterly revenue and earnings before marke...

1 day ago - Invezz

Pre-Markets Opens Flat

Pre-Markets Opens Flat

Other symbols:NEETSLAVZ
1 day ago - Zacks Investment Research

Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up

Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

1 day ago - Zacks Investment Research

Abbot Labs and Biogen Outshine Novavax in the Health Care Sector

Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including t...

Other symbols:BIIB
1 day ago - Benzinga

Abbott (ABT) Q3 Earnings and Revenues Beat Estimates

Abbott (ABT) delivered earnings and revenue surprises of 52.17% and 15.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Why Abbott Shares Are Rising Today

Abbott Laboratories (NYSE: ABT) is trading higher Wednesday after the company announced better-than-expected third-quarter financial results and raised guidance.  Abbott reported quarterly earnings of $...

1 day ago - Benzinga

Abbott's Q3 Profit Jumps 70% On Robust COVID-19 Test Sales

Abbott Laboratories (NYSE: ABT) reported a 70.5% rise in quarterly profit to $2.1 billion, helped by strength in its medical devices and diagnostics businesses due to a rebound in COVID-19 test sales am...

1 day ago - Benzinga

Abbott raises annual profit forecast after upbeat quarterly results

(Reuters) -Abbott Laboratories raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sa...

1 day ago - Reuters

Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance

ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

1 day ago - PRNewsWire

5 Must-See Earnings Charts This Week

What's going on in the economy? These five companies will give us some clues this week.

Other symbols:HONLADLRCXWGO
1 day ago - Zacks Investment Research

Abbott Laboratories's Earnings Outlook

Abbott Laboratories(NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.

2 days ago - Benzinga

Will Abbott Stock Rise After Its Q3 Results?

Abbott is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its e...

2 days ago - Forbes

Why Earnings Season Could Be Great for Abbott (ABT)

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 days ago - Zacks Investment Research

3 Solid Growth Stocks Perfect for Retirees

In order to combat the effects of inflation, all retirees need some exposure to growth in their portfolios.

Other symbols:FBRCII
4 days ago - The Motley Fool

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

6 days ago - Zacks Investment Research

Abbott (ABT) Gains But Lags Market: What You Should Know

In the latest trading session, Abbott (ABT) closed at $117.57, marking a +0.49% move from the previous day.

6 days ago - Zacks Investment Research

Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings

Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.

1 week ago - Zacks Investment Research

White House pushes back on Abbott's executive order

CNBC's Seema Mody reports on the Biden administration's response to Texas Gov. Abbott's ban of vaccine mandates among employers in the state.

1 week ago - CNBC Television

Abbott President & CEO Robert Ford on revolutionizing COVID-19 at-home testing technology

On this episode of Yahoo Finance Presents, Abbott President & CEO Robert Ford, sat down with Yahoo Finance's Anjalee Khemlani to discuss Abbott's upcoming keynote address at CES 2022 and COVID-19 test p...

Other symbols:F
1 week ago - Yahoo Finance

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Abbott (ABT) closed at $117.91, marking a +1.22% move from the previous day.

1 week ago - Zacks Investment Research

Abbott Labs CEO on demand for Covid-19 tests amid delta variant

Abbott Laboratories CEO Robert Ford joins 'TechCheck' to explain why he's confident the company can supply Covid-19 testing to meet demand and whether Abbott is considering investing in AI software.

2 weeks ago - CNBC Television

Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System

The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.

2 weeks ago - Zacks Investment Research